Proton radiotherapy is a high-cost, limited resource, for which the most robust evidence-based indications are in pediatric cancers owing to its ability to reduce long-term adverse effects compared with photon therapy.1-3 Most proton radiotherapy facilities are located in metropolitan areas or at major academic centers, and therefore require physician referral to the center for treatment. In addition, radiotherapy involves daily treatment for up to 8 weeks, requiring patients to potentially relocate to obtain treatment. Owing to the potential barriers to proton radiotherapy access, we aimed to assess the association of race and socioeconomic factors with proton use in patients with solid malignant diseases enrolled on Children’s Oncology Group (COG) prospective trials.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bitterman DS, Bona K, Laurie F, et al. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children’s Oncology Group Trials. JAMA Oncol. 2020;6(9):1465–1468. doi:10.1001/jamaoncol.2020.2259
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: